Bioxyne Limited (ASX:BXN)

Market Cap	227.06M +238.3%
Revenue (ttm)	47.95M +178.2%
Net Income	8.97M +300.8%
EPS	0.00 +259.9%
Shares Out	227.06M
PE Ratio	252.02
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,199,711
Open	0.0980
Previous Close	0.0970
Day's Range	0.0950 - 0.1050
52-Week Range	0.0950 - 1.1000
Beta	0.58
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Bioxyne

Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Online, and Retail) of Consumer Health and Novel Food Products; and Wholesale of Patented Probiotics segments. The company offers active pharmaceutical ingr...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 1998
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: BXN

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 24, 2026

Data Sources Report a data error